Theralase Technologies Inc. provided an update to its Phase II Bacillus Calmette Guerin -Unresponsive Non-Muscle invasive Bladder Cancer Carcinoma In-Situ (with or without resected Ta /T1 papillary disease) clinical study . To date, Theralase has enrolled and provided the primary Study II Treatment for 62 patients. For patients that received the optimized Study II Treatment the CR, IR and Total Responders are detailed below by assessment visit.

Theralase is currently working with its clinical study sites in Canada and the United States to compile information requested by the Food and Drug Administration for re-submission of a pre-Break Through Designation . If the pre-BTD submission is successful, this could lead to BTD approval. The Theralase®?

RuvidarTM-based Anti-Cancer Therapy has shown remarkable single-agent activity by proving to be safe and effective on a very difficult to treat BCG-Unresponsive patient population that has been diagnosed with high-grade NMIBC CIS, with or without resected Ta/T1 papillary tumors. The Theralase RuvidarTM-based Anti-Cancer therapy has shown remarkablesingle-agent activity by proving to been safe and effective on a very hard to treat BCG-Un responsive patient population that has been diagnosed With high-grade NMIBCIS, with or without resecting Ta /T1 papillary tumors. Mr. Roger DuMoulin-White, BSc, P.Eng, Pro.

Dir, President and Chief Executive Officer of Theralase stated, "To date, the Theralase Study II clinical data has demonstrated best-in-class performance for a single agent, providing high efficacy, durable response and a high safety profile, with no serious adverse events directly related to RuvidarTM or the TLC-3200 Medical Laser System. Theralase hopes to complete patient enrollment with accompanying administration of the primary, secondary and tertiary endpoints of these patients by 2026. FLS may be identified by the use of the words " may, "should", "ant anticipates", "bel believes", "plans", "ex expects", "estimate", "pot potential for" and similar expressions; including, statements related to the current expectations of the Company's management for future research, development and commercialization of the Company's PDCs and their drug formulations; including: preclinical research, clinical studies and development and regulatory approvals.

These statements involve significant risks, uncertainties and assumptions; including, whether the Company is able to: adequately fund and secure the requisite regulatory approvals to successfully complete preclinical and clinical studies in a timely fashion to implement its development plan; successfully commercialize its drug formulations; access sufficient capital to fund the Company's operations, which may not be available on terms that are commercially favorable to the Company or at all; provide preclinical and clinical support that the Company's drug formulations are effective against the conditions tested in its preclinical and clinical studies; comply with the term of license agreements with third parties, not to be in the United States, not to be in the U.S.